Taija Korpela
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Taija Korpela has a total of 61 co-authors. Here are the top co-authors by number of shared publications:
- Gabriele Capurso
Pancreatobiliary Endoscopy and Endosonography Division, IRCCS San Raffaele Scientific Institute, Italy
4 shared publications Leena Kylänpää
Gastroenterological Surgery, Abdominal Center, Helsinki University Hospital and University of Helsinki, Helsinki, Finland
4 shared publications- Livia Archibugi
Pancreatico-Biliary Endoscopy and Endosonography Division, Pancreas Translational and Clinical Research Center, IRCCS San Raffaele Hospital, Milan, Italy
4 shared publications Marianne Udd
Gastroenterological Surgery, Abdominal Center, Helsinki University Hospital and University of Helsinki, Helsinki, Finland
4 shared publications- Marianne Udd
Gastrointestinal Surgery, Helsinki University Central Hospital, Helsinki, Finland
4 shared publications - Davor Stimac
Division of Internal Medicine, University Hospital, Rijeka, Croatia.
3 shared publications
Latest Publications
- 13 March 2025
- Published by Taylor & Francis in Scandinavian Journal of Gastroenterology
- Vol. 60 (4) , 386-393
Stone density can predict the number of ESWL treatments needed in patients with pancreatic duct calculi
Extracorporeal shock wave lithotripsy (ESWL) with endotherapy (ET) is the first-line treatment in patients with chronic pancreatitis (CP) and main pancreatic duct stone (PDS). Our study aimed to evaluate factors that predict the outcome of ESWL in CP patients with PDS. We retrospectively analyzed data of 166 patients with CP and radiopaque PDS. Computed tomography (CT) images were evaluated for stone density, stone size, main pancreatic duct (MPD) size, and skin-to-stone distance (SSD). Long-term pain relief results were determined via telephone interview in 100 patients. Mean stone density (MSD) > 1336 HU predicted the need to perform more than one ESWL session (odds ratio [OR]: 1.002; 95% confidence interval [CI]: 1.001 to 1.003; p = 0.002), cut-off 1336 HU yielding 71% sensitivity and 65% specificity. Denser stones required more ESWL and following ET, with ≥4 ET sessions resulting in better technical success. (OR: 3.222; 95% CI: 1.240 to 8.371; p = 0.016). Overall technical success (complete stone fragmentation in ESWL or placing a stent past the stone in ET) rate was 81.3%. Clinical success (complete or partial pain relief at the end of the treatments) rate was 83.7% and remained at the same level also in the long-term follow-up (median 5.5 years). Stone size, MPD size, or SSD were not associated with any of the study outcomes. Higher MSD than 1336 HU predicts the need for more than one ESWL and ET sessions to fragment the stone and clear the duct, but when successful the long-term result is favorable.
- 13 March 2025
- Published by Taylor & Francis in Scandinavian Journal of Gastroenterology
- Vol. 60 (4) , 386-393
Stone density can predict the number of ESWL treatments needed in patients with pancreatic duct calculi
Extracorporeal shock wave lithotripsy (ESWL) with endotherapy (ET) is the first-line treatment in patients with chronic pancreatitis (CP) and main pancreatic duct stone (PDS). Our study aimed to evaluate factors that predict the outcome of ESWL in CP patients with PDS. We retrospectively analyzed data of 166 patients with CP and radiopaque PDS. Computed tomography (CT) images were evaluated for stone density, stone size, main pancreatic duct (MPD) size, and skin-to-stone distance (SSD). Long-term pain relief results were determined via telephone interview in 100 patients. Mean stone density (MSD) > 1336 HU predicted the need to perform more than one ESWL session (odds ratio [OR]: 1.002; 95% confidence interval [CI]: 1.001 to 1.003; p = 0.002), cut-off 1336 HU yielding 71% sensitivity and 65% specificity. Denser stones required more ESWL and following ET, with ≥4 ET sessions resulting in better technical success. (OR: 3.222; 95% CI: 1.240 to 8.371; p = 0.016). Overall technical success (complete stone fragmentation in ESWL or placing a stent past the stone in ET) rate was 81.3%. Clinical success (complete or partial pain relief at the end of the treatments) rate was 83.7% and remained at the same level also in the long-term follow-up (median 5.5 years). Stone size, MPD size, or SSD were not associated with any of the study outcomes. Higher MSD than 1336 HU predicts the need for more than one ESWL and ET sessions to fragment the stone and clear the duct, but when successful the long-term result is favorable.
- Open Access
- 9 November 2023
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 44 (Supplement)
Ascending aortic length associates to acute aortic dissection
Background: Acute Stanford type A aortic dissection is a life-threatening condition that is challenging to predict and prevent. The risk for aortic dissection is known to increase with ascending aortic (AA) dilatation, which sets indication for preventive aortic replacement. Anyhow, most of the dissections occur before aortic diameter reaches the diameter indications of preventive surgery. Purpose: To investigate whether, alongside with aortic dilatation, AA elongation affects the increased risk for aortic dissection. Methods: This retrospective study included patients treated for Stanford type A aortic dissection (n=102), patients with AA dilatation (max. diameter > 40 mm) (n=134) and healthy controls (n=191). AA length and dimensions were measured from aortic computed tomography angiography (CTA) images. The AA length was defined as a distance between the aortic annulus to the origin of the brachiocephalic trunk. Results: AA length was significantly increased in patients with aortic dissection when compared to patients with AA dilatation and to healthy controls (106.2 ± 15.1 mm vs. 96.8 ± 11.2 mm vs. 82.5 ± 8.1 mm; p<0.001). After adjusting AA length to patient's height, BSA, sex and maximal diameter, adjusted length of AA was 99.8 mm in the dissection group, 94.4 mm in the AA dilatation group and 86.0 mm in healthy controls. Thus, when comparing adjusted AA length between the groups, dissected aortas were 13.8 mm longer than in healthy controls and 5.4 mm longer than in dilated non-dissected aortas (p<0.001). Dilated non-dissected aortas were 8.4 mm longer than in healthy controls (p<0.001). In the dissection cohort, 25/102 (24.5%) patients had maximal AA diameter 110 mm (Table). By combining 110 mm AA length and <55 mm diameter, 58% of the dissection patients would have been identified instead of using only AA diameter ≥55 mm as a cut-off criteria, based on which only 33% patients met the indication for elective surgery. Conclusions: To conclude, AA length seems to be a strong predictor of risk of type A aortic dissection and thus might be used as an additional tool in identifying patients for preventive surgery.Cut off - limits
- 9 November 2023
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 44 (Supplement)
Open AccessAscending aortic length associates to acute aortic dissection
Background: Acute Stanford type A aortic dissection is a life-threatening condition that is challenging to predict and prevent. The risk for aortic dissection is known to increase with ascending aortic (AA) dilatation, which sets indication for preventive aortic replacement. Anyhow, most of the dissections occur before aortic diameter reaches the diameter indications of preventive surgery. Purpose: To investigate whether, alongside with aortic dilatation, AA elongation affects the increased risk for aortic dissection. Methods: This retrospective study included patients treated for Stanford type A aortic dissection (n=102), patients with AA dilatation (max. diameter > 40 mm) (n=134) and healthy controls (n=191). AA length and dimensions were measured from aortic computed tomography angiography (CTA) images. The AA length was defined as a distance between the aortic annulus to the origin of the brachiocephalic trunk. Results: AA length was significantly increased in patients with aortic dissection when compared to patients with AA dilatation and to healthy controls (106.2 ± 15.1 mm vs. 96.8 ± 11.2 mm vs. 82.5 ± 8.1 mm; p<0.001). After adjusting AA length to patient's height, BSA, sex and maximal diameter, adjusted length of AA was 99.8 mm in the dissection group, 94.4 mm in the AA dilatation group and 86.0 mm in healthy controls. Thus, when comparing adjusted AA length between the groups, dissected aortas were 13.8 mm longer than in healthy controls and 5.4 mm longer than in dilated non-dissected aortas (p<0.001). Dilated non-dissected aortas were 8.4 mm longer than in healthy controls (p<0.001). In the dissection cohort, 25/102 (24.5%) patients had maximal AA diameter 110 mm (Table). By combining 110 mm AA length and <55 mm diameter, 58% of the dissection patients would have been identified instead of using only AA diameter ≥55 mm as a cut-off criteria, based on which only 33% patients met the indication for elective surgery. Conclusions: To conclude, AA length seems to be a strong predictor of risk of type A aortic dissection and thus might be used as an additional tool in identifying patients for preventive surgery.Cut off - limits
- Open Access
- 3 January 2022
- Published by Springer Nature in BMC Cancer
- Vol. 22 (1) , 1-12
Pancreatic fibrosis, acinar atrophy and chronic inflammation in surgical specimens associated with survival in patients with resectable pancreatic ductal adenocarcinoma
Background: Pancreatic ductal adenocarcinoma (PDAC), one of the most lethal malignancies, is increasing in incidence. However, the stromal reaction pathophysiology and its role in PDAC development remain unknown. We, therefore, investigated the potential role of histological chronic pancreatitis findings and chronic inflammation on surgical PDAC specimens and disease-specific survival (DSS). Methods: Between 2000 and 2016, we retrospectively enrolled 236 PDAC patients treated with curative-intent pancreatic surgery at Helsinki University Hospital. All pancreatic transection margin slides were re-reviewed and histological findings were evaluated applying international guidelines. Results: DSS among patients with no fibrosis, acinar atrophy or chronic inflammation identified on pathology slides was significantly better than DSS among patients with fibrosis, acinar atrophy and chronic inflammation [median survival: 41.8 months, 95% confidence interval (CI) 26.0–57.6 vs. 20.6 months, 95% CI 10.3–30.9; log-rank test p = 0.001]. Multivariate analysis revealed that Ca 19–9 > 37 kU/l [hazard ratio (HR) 1.48, 95% CI 1.02–2.16], lymph node metastases N1–2 (HR 1.71, 95% CI 1.16–2.52), tumor size > 30 mm (HR 1.47, 95% CI 1.04–2.08), the combined effect of fibrosis and acinar atrophy (HR 1.91, 95% CI 1.27–2.88) and the combined effect of fibrosis, acinar atrophy and chronic inflammation (HR 1.63, 95% CI 1.03–2.58) independently served as unfavorable prognostic factors for DSS. However, we observed no significant associations between tumor size (> 30 mm) and the degree of perilobular fibrosis (p = 0.655), intralobular fibrosis (p = 0.587), acinar atrophy (p = 0.584) or chronic inflammation (p = 0.453). Conclusions: Our results indicate that the pancreatic stroma is associated with PDAC patients’ DSS. Additionally, the more severe the fibrosis, acinar atrophy and chronic inflammation, the worse the impact on DSS, thereby warranting further studies investigating stroma-targeted therapies.
- 3 January 2022
- Published by Springer Nature in BMC Cancer
- Vol. 22 (1) , 1-12
Open AccessPancreatic fibrosis, acinar atrophy and chronic inflammation in surgical specimens associated with survival in patients with resectable pancreatic ductal adenocarcinoma
Background: Pancreatic ductal adenocarcinoma (PDAC), one of the most lethal malignancies, is increasing in incidence. However, the stromal reaction pathophysiology and its role in PDAC development remain unknown. We, therefore, investigated the potential role of histological chronic pancreatitis findings and chronic inflammation on surgical PDAC specimens and disease-specific survival (DSS). Methods: Between 2000 and 2016, we retrospectively enrolled 236 PDAC patients treated with curative-intent pancreatic surgery at Helsinki University Hospital. All pancreatic transection margin slides were re-reviewed and histological findings were evaluated applying international guidelines. Results: DSS among patients with no fibrosis, acinar atrophy or chronic inflammation identified on pathology slides was significantly better than DSS among patients with fibrosis, acinar atrophy and chronic inflammation [median survival: 41.8 months, 95% confidence interval (CI) 26.0–57.6 vs. 20.6 months, 95% CI 10.3–30.9; log-rank test p = 0.001]. Multivariate analysis revealed that Ca 19–9 > 37 kU/l [hazard ratio (HR) 1.48, 95% CI 1.02–2.16], lymph node metastases N1–2 (HR 1.71, 95% CI 1.16–2.52), tumor size > 30 mm (HR 1.47, 95% CI 1.04–2.08), the combined effect of fibrosis and acinar atrophy (HR 1.91, 95% CI 1.27–2.88) and the combined effect of fibrosis, acinar atrophy and chronic inflammation (HR 1.63, 95% CI 1.03–2.58) independently served as unfavorable prognostic factors for DSS. However, we observed no significant associations between tumor size (> 30 mm) and the degree of perilobular fibrosis (p = 0.655), intralobular fibrosis (p = 0.587), acinar atrophy (p = 0.584) or chronic inflammation (p = 0.453). Conclusions: Our results indicate that the pancreatic stroma is associated with PDAC patients’ DSS. Additionally, the more severe the fibrosis, acinar atrophy and chronic inflammation, the worse the impact on DSS, thereby warranting further studies investigating stroma-targeted therapies.
- 12 March 2020
- Published by Wiley in International Journal of Cancer
- Vol. 147 (5) , 1450-1460
Association between chronic pancreatitis and pancreatic cancer: A 10‐year retrospective study of endoscopically treated and surgical patients
Pancreatic cancer (PC) has a poor prognosis. Chronic pancreatitis (CP) associates with high morbidity and mortality, and serves as a risk factor for PC. Our study aimed to assess the association between endoscopically treated CP patients and PC, and to establish the rate of CP among patients undergoing surgery for pancreatic ductal adenocarcinoma (PDAC). We retrospectively analyzed 458 CP patients undergoing endoscopic treatment (ET) between 2000 and 2010 and 349 PDAC patients undergoing pancreatic resection between 2000 and 2014 at the Helsinki University Hospital. The likelihood of diagnosing PC was highest within 2 years of a CP diagnosis: 21 of 30 PC diagnoses occurred during this time. After 2 years follow‐up: 9 of 30 PC diagnoses occurred 2–12 years from CP diagnosis. Two patients were diagnosed with CP before PDAC. Multivariate analysis showed two prognostic factors indicative of PC development: biliary stricture (HR 9.21; 95% CI 3.76–22.08) and a higher age (per 5‐year increases) at CP onset (HR 1.55; 95% CI 1.30–1.85). Among 458 CP patients, the median overall survival without PC was 14.7 years (95% CI 12.0–17.3), falling to 1.6 years (95% CI 1.2–2.0) with PC. The high incidence of PC among CP patients at the beginning of follow‐up likely reflected an initially missed PC diagnoses. In long‐term follow‐up, an increasing PC incidence might reflect the PC‐predisposing impact of CP. Thus, we recommend careful follow‐up for patients presenting with a recently diagnosed CP and risk factors for PC.
- 12 March 2020
- Published by Wiley in International Journal of Cancer
- Vol. 147 (5) , 1450-1460
Association between chronic pancreatitis and pancreatic cancer: A 10‐year retrospective study of endoscopically treated and surgical patients
Pancreatic cancer (PC) has a poor prognosis. Chronic pancreatitis (CP) associates with high morbidity and mortality, and serves as a risk factor for PC. Our study aimed to assess the association between endoscopically treated CP patients and PC, and to establish the rate of CP among patients undergoing surgery for pancreatic ductal adenocarcinoma (PDAC). We retrospectively analyzed 458 CP patients undergoing endoscopic treatment (ET) between 2000 and 2010 and 349 PDAC patients undergoing pancreatic resection between 2000 and 2014 at the Helsinki University Hospital. The likelihood of diagnosing PC was highest within 2 years of a CP diagnosis: 21 of 30 PC diagnoses occurred during this time. After 2 years follow‐up: 9 of 30 PC diagnoses occurred 2–12 years from CP diagnosis. Two patients were diagnosed with CP before PDAC. Multivariate analysis showed two prognostic factors indicative of PC development: biliary stricture (HR 9.21; 95% CI 3.76–22.08) and a higher age (per 5‐year increases) at CP onset (HR 1.55; 95% CI 1.30–1.85). Among 458 CP patients, the median overall survival without PC was 14.7 years (95% CI 12.0–17.3), falling to 1.6 years (95% CI 1.2–2.0) with PC. The high incidence of PC among CP patients at the beginning of follow‐up likely reflected an initially missed PC diagnoses. In long‐term follow‐up, an increasing PC incidence might reflect the PC‐predisposing impact of CP. Thus, we recommend careful follow‐up for patients presenting with a recently diagnosed CP and risk factors for PC.
- 1 September 2019
- Published by Elsevier in Pancreatology
- Vol. 19, S189-S190
Chronic use of statins and acetylsalicylic acid and incidence of post-ERCP acute pancreatitis. Data from the STARK project, a prospective international, multicenter, cohort study
- 1 September 2019
- Published by Elsevier in Pancreatology
- Vol. 19, S189-S190
Chronic use of statins and acetylsalicylic acid and incidence of post-ERCP acute pancreatitis. Data from the STARK project, a prospective international, multicenter, cohort study
- 4 March 2019
- Published by Taylor & Francis in Scandinavian Journal of Gastroenterology
- Vol. 54 (3) , 365-370
Fully covered self-expanding metal stents for benign refractory pancreatic duct strictures in chronic pancreatitis
Background: Pancreatic duct (PD) stricture is a common adverse event in chronic pancreatitis (CP). Primary treatment for refractory PD strictures is endotherapy (ET), including the insertion of multiple plastic stents. In addition, fully covered self-expandable metal stents (FC-SEMSs) have also been successfully used. More long-term studies are necessary to clarify the complication rate and efficiency, however. Methods: This retrospective study was comprised of 17 patients with symptomatic CP and refractory fibrotic main pancreatic duct (MPD) stricture treated with FC-SEMSs between 2010–2018 at the Helsinki University Hospital. Treated strictures were located in the pancreatic head. Technical success was defined as the accurate positioning of the stent and resolution of the MPD stricture. Clinical success was defined as pain relief at the end of the follow-up. Results: In 12 patients (71%), stricture resolution was accomplished. Clinical success was achieved in 12 patients (71%). The median duration of stenting was 169 days (range 15–804). Ten patients (58.8%) underwent a follow-up of two years or more. Early complications (≤7 days) occurred in two patients (12%): one pancreatitis and one cholestasis. Late complications (≥7 days) included severe abdominal pain (n = 2, 12%), pancreatitis (n = 3, 18%), cholestasis (n = 1, 6%) and stent migration (n = 7, 35%). Significant differences in stricture resolution and pain improvement were evident in patients with stent migration compared to patients without stent migration [1(14.3%) vs. 11(84.6%), p = .004 and 2(28.6%) vs. 11(84.6%), p = .022]. Conclusion: FC-SEMS placement is a safe and potentially effective treatment for this challenging group of patients. However, stent migration appears to affect the clinical and technical outcome.
- 4 March 2019
- Published by Taylor & Francis in Scandinavian Journal of Gastroenterology
- Vol. 54 (3) , 365-370
Fully covered self-expanding metal stents for benign refractory pancreatic duct strictures in chronic pancreatitis
Background: Pancreatic duct (PD) stricture is a common adverse event in chronic pancreatitis (CP). Primary treatment for refractory PD strictures is endotherapy (ET), including the insertion of multiple plastic stents. In addition, fully covered self-expandable metal stents (FC-SEMSs) have also been successfully used. More long-term studies are necessary to clarify the complication rate and efficiency, however. Methods: This retrospective study was comprised of 17 patients with symptomatic CP and refractory fibrotic main pancreatic duct (MPD) stricture treated with FC-SEMSs between 2010–2018 at the Helsinki University Hospital. Treated strictures were located in the pancreatic head. Technical success was defined as the accurate positioning of the stent and resolution of the MPD stricture. Clinical success was defined as pain relief at the end of the follow-up. Results: In 12 patients (71%), stricture resolution was accomplished. Clinical success was achieved in 12 patients (71%). The median duration of stenting was 169 days (range 15–804). Ten patients (58.8%) underwent a follow-up of two years or more. Early complications (≤7 days) occurred in two patients (12%): one pancreatitis and one cholestasis. Late complications (≥7 days) included severe abdominal pain (n = 2, 12%), pancreatitis (n = 3, 18%), cholestasis (n = 1, 6%) and stent migration (n = 7, 35%). Significant differences in stricture resolution and pain improvement were evident in patients with stent migration compared to patients without stent migration [1(14.3%) vs. 11(84.6%), p = .004 and 2(28.6%) vs. 11(84.6%), p = .022]. Conclusion: FC-SEMS placement is a safe and potentially effective treatment for this challenging group of patients. However, stent migration appears to affect the clinical and technical outcome.
- 20 August 2018
- Published by Elsevier in Digestive and Liver Disease
- Vol. 50 (12) , 1362-1365
Chronic use of statins and risk of post-ERCP acute pancreatitis (STARK): Study protocol for an international multicenter prospective cohort study
- 20 August 2018
- Published by Elsevier in Digestive and Liver Disease
- Vol. 50 (12) , 1362-1365
Chronic use of statins and risk of post-ERCP acute pancreatitis (STARK): Study protocol for an international multicenter prospective cohort study
- 7 February 2016
- Published by Taylor & Francis in Scandinavian Journal of Gastroenterology
- Vol. 51 (7) , 866-871
Long-term results of combined ESWL and ERCP treatment of chronic calcific pancreatitis
Objective: Extracorporeal shock wave lithotripsy (ESWL) combined with endotherapy (ET) is the standard treatment for pancreatic duct stones (PDS) in chronic pancreatitis (CP). Our aim was to report the short- and long-term results of ESWL and ET. Material and methods: Consecutively treated 83 patients with symptomatic PDS using ESWL and ET. Success was defined (i) technically: PDS fragmentation and clearance obtained and (ii) clinically: improvement/resolution of pain. To get information on quality of life, we conducted a phone survey whereby we contacted 64 (89%) patients. The long-term results are presented in those patients with ≥2 years follow-up. Results: Treated PDS with median size of 10 (5–25) mm were located in the head, body, or the tail of the pancreas in 78, 4, and 1 patients, respectively. The primary results were that technical success was achieved in 69 patients (83%) and clinical success in 66 patients (80%). Fourteen patients had technical failure, but eight of them became free of pain. Thus, clinical success can be considered to have been achieved in 74 of 83 patients (89%). In patients with persistent pseudocyst (PC) at the time of ESWL (n = 19), the PC disappeared in a year in 14 patients (74%). The long-term results were obtained from 61 (73%) ESWL- and ET-treated patients. The median follow-up for them was 53 months (range: 24–124) and 57 patients (93%) became pain-free or had less pain. Conclusions: For patients with CP and PDS ESWL combined with ET is an effective and safe treatment giving favorable long-term results.
- 7 February 2016
- Published by Taylor & Francis in Scandinavian Journal of Gastroenterology
- Vol. 51 (7) , 866-871
Long-term results of combined ESWL and ERCP treatment of chronic calcific pancreatitis
Objective: Extracorporeal shock wave lithotripsy (ESWL) combined with endotherapy (ET) is the standard treatment for pancreatic duct stones (PDS) in chronic pancreatitis (CP). Our aim was to report the short- and long-term results of ESWL and ET. Material and methods: Consecutively treated 83 patients with symptomatic PDS using ESWL and ET. Success was defined (i) technically: PDS fragmentation and clearance obtained and (ii) clinically: improvement/resolution of pain. To get information on quality of life, we conducted a phone survey whereby we contacted 64 (89%) patients. The long-term results are presented in those patients with ≥2 years follow-up. Results: Treated PDS with median size of 10 (5–25) mm were located in the head, body, or the tail of the pancreas in 78, 4, and 1 patients, respectively. The primary results were that technical success was achieved in 69 patients (83%) and clinical success in 66 patients (80%). Fourteen patients had technical failure, but eight of them became free of pain. Thus, clinical success can be considered to have been achieved in 74 of 83 patients (89%). In patients with persistent pseudocyst (PC) at the time of ESWL (n = 19), the PC disappeared in a year in 14 patients (74%). The long-term results were obtained from 61 (73%) ESWL- and ET-treated patients. The median follow-up for them was 53 months (range: 24–124) and 57 patients (93%) became pain-free or had less pain. Conclusions: For patients with CP and PDS ESWL combined with ET is an effective and safe treatment giving favorable long-term results.